A5001823716- Esophageal and GI Pathology
- Gallbladder and Bile Duct Disorders
- Dysphagia Assessment and Management
- Liver Disease Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Gastroesophageal reflux and treatments
- Pediatric Hepatobiliary Diseases and Treatments
- Colorectal Cancer Screening and Detection
- Pancreatitis Pathology and Treatment
- Organ Transplantation Techniques and Outcomes
- Tracheal and airway disorders
- Clostridium difficile and Clostridium perfringens research
- Liver Diseases and Immunity
- Biliary and Gastrointestinal Fistulas
- Pancreatic and Hepatic Oncology Research
- Sarcoma Diagnosis and Treatment
- Potassium and Related Disorders
- Liver Disease and Transplantation
- Bariatric Surgery and Outcomes
- Gastrointestinal disorders and treatments
- Microscopic Colitis
- Atrial Fibrillation Management and Outcomes
- Intestinal Malrotation and Obstruction Disorders
- Social Media in Health Education
- Pneumothorax, Barotrauma, Emphysema
Brown University
2017-2025
Lahey Medical Center
2024
Lahey Hospital and Medical Center
2021-2024
Thomas Jefferson University Hospital
2020-2021
Rhode Island Hospital
2019
Providence College
2019
Saint Francis Hospital
2017
Hartford Financial Services (United States)
2017
Yale University
2015-2017
Saint Francis University
2017
Abstract EUS-guided gallbladder drainage (EUS-GBD) using lumen apposing metal stents (LAMS) has excellent technical and short-term clinical success for acute cholecystitis (AC). The goals of this study were to determine the long-term outcomes adverse events (AEs) EUS-GBD with LAMS. A multicenter, retrospective was conducted at 18 US tertiary care institutions. Inclusion criteria: any AC patient attempted LAMS minimum 30-day post-procedure follow-up. Long-term defined as absence recurrent...
We evaluated serial fecal microbiota transplant (FMT) by retention enema in patients with severe or severe/complicated Clostridoides difficile infection (CDI) unresponsive to at least 48 hours of standard antibiotic therapy. Of the 15 included, despite initial improvement most patients, only 5 sustained cure 30 days, and serious adverse events occurred 4 patients.
Potassium permanganate is a dark purple or bronze colored crystalline solid that has blue metallic appearance in light. It an odorless substance readily accessible powder tablet form and clinically used as topical antiseptic antifungal agent. Ingestion can lead to the formation potassium hydroxide, strong alkaline agent, cause liquefaction necrosis leading significant damage mucosa when ingested. Here we present case of ingestion. A 36 year old male with history treatment naïve hepatitis C...